DK171094B1 - Anvendelse af et benzamidderivat til fremstilling af et middel til behandling eller forebyggelse af cognitive lidelser - Google Patents

Anvendelse af et benzamidderivat til fremstilling af et middel til behandling eller forebyggelse af cognitive lidelser Download PDF

Info

Publication number
DK171094B1
DK171094B1 DK036889A DK36889A DK171094B1 DK 171094 B1 DK171094 B1 DK 171094B1 DK 036889 A DK036889 A DK 036889A DK 36889 A DK36889 A DK 36889A DK 171094 B1 DK171094 B1 DK 171094B1
Authority
DK
Denmark
Prior art keywords
moclobemide
test
tablets
preparation
cognitive disorders
Prior art date
Application number
DK036889A
Other languages
Danish (da)
English (en)
Other versions
DK36889D0 (da
DK36889A (da
Inventor
Roman Amrein
Ravi Anand
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of DK36889D0 publication Critical patent/DK36889D0/da
Publication of DK36889A publication Critical patent/DK36889A/da
Application granted granted Critical
Publication of DK171094B1 publication Critical patent/DK171094B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK036889A 1988-01-28 1989-01-27 Anvendelse af et benzamidderivat til fremstilling af et middel til behandling eller forebyggelse af cognitive lidelser DK171094B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH29888 1988-01-28
CH29888 1988-01-28

Publications (3)

Publication Number Publication Date
DK36889D0 DK36889D0 (da) 1989-01-27
DK36889A DK36889A (da) 1989-07-29
DK171094B1 true DK171094B1 (da) 1996-06-03

Family

ID=4183804

Family Applications (1)

Application Number Title Priority Date Filing Date
DK036889A DK171094B1 (da) 1988-01-28 1989-01-27 Anvendelse af et benzamidderivat til fremstilling af et middel til behandling eller forebyggelse af cognitive lidelser

Country Status (15)

Country Link
US (1) US4906626A (fr)
EP (1) EP0326023B1 (fr)
JP (1) JPH07116043B2 (fr)
KR (1) KR960016203B1 (fr)
AT (1) ATE113207T1 (fr)
AU (1) AU620584B2 (fr)
CA (1) CA1332151C (fr)
DE (1) DE58908544D1 (fr)
DK (1) DK171094B1 (fr)
ES (1) ES2063060T3 (fr)
HU (1) HU203042B (fr)
IE (1) IE65409B1 (fr)
IL (1) IL89031A (fr)
PH (1) PH26030A (fr)
ZA (1) ZA89523B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551963A3 (en) * 1986-12-17 1993-09-01 Glaxo Group Limited Use of heterocyclic derivatives for the manufacture of medicaments
FR2645742A1 (fr) * 1989-04-12 1990-10-19 Delagrange Laboratoires Application de derives de 2-methoxy 4-(4,5-dihydro 2-imidazolyl (ou 2-oxazolyl) amino) 5-chloro benzamide dans le traitement des troubles de la fonction cognitive
JP3172202B2 (ja) * 1990-11-29 2001-06-04 エフ．ホフマン−ラ ロシュ アーゲー 不安の障害の処置剤
US6951884B2 (en) * 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
DE602004017206D1 (de) * 2003-10-23 2008-11-27 Hoffmann La Roche Benzazepin-derivate als mao-b-hemmer
EP1713486A4 (fr) * 2003-12-02 2009-04-29 Sheldon Leslie James Therapie combinee pour le traitement de la demence, la depression et l'apathie
ES2572263T3 (es) 2005-10-25 2016-05-31 Shionogi & Co Derivados de dihidrooxazina y tetrahidropirimidina como inhibidores de BACE 1
EP2147914B1 (fr) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Dérivés d'aminodihydrothiazine substitués par des groupes cycliques
EP2151435A4 (fr) * 2007-04-24 2011-09-14 Shionogi & Co Composition pharmaceutique pour le traitement de la maladie d'alzheimer
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
EP2360155A4 (fr) * 2008-10-22 2012-06-20 Shionogi & Co 2-aminopyridin-4-one et dérivé de 2-aminopyridine dont l'activité inhibe la bace1
CN102834384A (zh) 2009-12-11 2012-12-19 盐野义制药株式会社 *嗪衍生物
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
WO2012057248A1 (fr) 2010-10-29 2012-05-03 塩野義製薬株式会社 Dérivé de naphtyridine
EP2703399A4 (fr) 2011-04-26 2014-10-15 Shionogi & Co Dérivé d'oxazine et inhibiteur de bace 1 le contenant
WO2014065434A1 (fr) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1
EP3440508B1 (fr) 2016-04-12 2021-01-27 E- Vision Smart Optics, Inc. Lentilles électroactives avec ponts résistifs surélevés
US10599006B2 (en) 2016-04-12 2020-03-24 E-Vision Smart Optics, Inc. Electro-active lenses with raised resistive bridges

Also Published As

Publication number Publication date
HU203042B (en) 1991-05-28
JPH07116043B2 (ja) 1995-12-13
EP0326023A3 (en) 1990-09-05
IL89031A (en) 1995-07-31
JPH01224318A (ja) 1989-09-07
ATE113207T1 (de) 1994-11-15
EP0326023A2 (fr) 1989-08-02
HUT50042A (en) 1989-12-28
IE890273L (en) 1989-07-28
AU2883689A (en) 1989-08-03
DE58908544D1 (de) 1994-12-01
CA1332151C (fr) 1994-09-27
ZA89523B (en) 1989-09-27
AU620584B2 (en) 1992-02-20
IL89031A0 (en) 1989-08-15
DK36889D0 (da) 1989-01-27
EP0326023B1 (fr) 1994-10-26
PH26030A (en) 1992-01-29
ES2063060T3 (es) 1995-01-01
IE65409B1 (en) 1995-10-18
DK36889A (da) 1989-07-29
KR960016203B1 (ko) 1996-12-06
KR890011589A (ko) 1989-08-21
US4906626A (en) 1990-03-06

Similar Documents

Publication Publication Date Title
DK171094B1 (da) Anvendelse af et benzamidderivat til fremstilling af et middel til behandling eller forebyggelse af cognitive lidelser
Dunbar et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients
Casey et al. γ-Acetylenic GABA in tardive dyskinesia
US10265304B2 (en) Nootropic compositions for improving memory performance
Bartolomeo et al. The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist
US20130045988A1 (en) Combination therapy
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
Towse Cinnarizine—a labyrinthine sedative
CN112843005A (zh) 左乙拉西坦的延时释放药物组合物
CN116075302A (zh) GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法
Woodruff-Pak et al. Mecamylamine interactions with galantamine and donepezil: effects on learning, acetylcholinesterase, and nicotinic acetylcholine receptors
Vanderwolf et al. Effects of p-chlorophenylalanine and scopolamine on retention of habits in rats
CA2168265C (fr) Antidepresseur
RU2612791C1 (ru) Средства, улучшающие процесс обучения, памяти и когнитивные функции, а также для симптоматической терапии при аутистических расстройствах
CA2334611A1 (fr) Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles psychiatriques
Emmerling et al. In Vitro and In Vivo Effects of a Dual Inhibitor of Acetylcholinesterase and Muscarinic Receptors, CI-1002
JPS6213925B2 (fr)
WO2015105064A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de troubles rétiniens

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment
B1 Patent granted (law 1993)
PUP Patent expired